Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Corcept Therapeutics is conducting a Phase 2 study titled A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA). This study aims to evaluate the efficacy and safety of relacorilant, combined with nab-paclitaxel and bevacizumab, in treating patients with advanced ovarian cancer. The significance of this study lies in its potential to offer a new treatment option for this challenging cancer type.
The intervention being tested includes relacorilant, nab-paclitaxel, and bevacizumab. Relacorilant is administered orally, while nab-paclitaxel and bevacizumab are given via intravenous infusion. The purpose of these drugs is to assess their combined effectiveness in treating ovarian cancer.
This is an interventional study with a single-group assignment. There is no masking involved, meaning both researchers and participants know the treatment being administered. The primary purpose of the study is treatment-focused, aiming to determine the effectiveness of the drug combination.
The study began on April 11, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could significantly impact Corcept Therapeutics’ stock performance and investor sentiment, as successful results may lead to a new treatment option in the ovarian cancer market. This could position Corcept favorably against competitors in the oncology sector.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.